and why do they get this disease? There seems a lot more of it about in the last 5 yrs, naturally doctors are baffled; like there is more non-Hodgkin lymphoma; and cardiac issues; and clots; all very baffling; I know, it must be climate change!
That “unmet need” can ONLY be derived by adopting the perspective of “the phenotype based approach to the validation of biomarkers and discovery of novel targets”, a patent filed and then abandoned by your home institution (The University of California).
Look forward to whether you decide to take that deep dive!
Epithelial malignancies will NEVER respond satisfactorily to singly targeted therapies.
The patent turned the discovery platform on its head, by taking a bedside to bench approach towards diagnostics and rational (multimodal) intervention.
Whereas the strategy for how to accomplish that was in Lung cancers, the principles apply to all epithelial malignancies.
This is truly a devastating disease. Thank you for your clarifying analysis, it is always greatly appreciated 🙏🏼
and why do they get this disease? There seems a lot more of it about in the last 5 yrs, naturally doctors are baffled; like there is more non-Hodgkin lymphoma; and cardiac issues; and clots; all very baffling; I know, it must be climate change!
That “unmet need” can ONLY be derived by adopting the perspective of “the phenotype based approach to the validation of biomarkers and discovery of novel targets”, a patent filed and then abandoned by your home institution (The University of California).
Look forward to whether you decide to take that deep dive!
What is the connection of that patent to this article and what was the purpose of that patent to begin with?
Epithelial malignancies will NEVER respond satisfactorily to singly targeted therapies.
The patent turned the discovery platform on its head, by taking a bedside to bench approach towards diagnostics and rational (multimodal) intervention.
Whereas the strategy for how to accomplish that was in Lung cancers, the principles apply to all epithelial malignancies.